Liver-specific p38α deficiency causes reduced cell growth and cytokinesis failure during chronic biliary cirrhosis in mice

Hepatology

Volumn 57, Issue 5, 2013, Pages 1950-1961

  Tormos, Ana M ^a   Arduini, Alessandro ^a   Talens Visconti, Raquel ^a   Del Barco Barrantes, Ivan ^b   Nebreda, Angel R ^b,c   Sastre, Juan ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN D1; CYCLINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN KINASE B;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; BILIARY CIRRHOSIS; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CHOLESTASIS; CHRONIC BILIARY CIRRHOSIS; CONTROLLED STUDY; CYTOKINESIS; ENZYME SPECIFICITY; FIBROGENESIS; GENE EXPRESSION; HEPATOMEGALY; HISTOPATHOLOGY; INFLAMMATION; LIVER; LIVER CELL; MALE; MITOSIS INDEX; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; WILD TYPE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CHRONIC DISEASE; CYCLIN B1; CYCLIN D1; CYTOKINESIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEPATOCYTES; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MAP KINASE KINASE 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 14; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84876724417     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26174     Document Type: Article

References (34)

1. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-549.
2. Hui L, Bakiri L, Stepniak E, Wagner EF. P38alpha: A suppressor of cell proliferation and tumorigenesis. Cell Cycle 2007; 6: 2429-2433.
3. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-jun pathway. Nat Genet 2007; 39: 741-749.
4. Awad MM, Enslen H, Boylan JM, Davis RJ, Gruppuso PA. Growth regulation via p38 mitogen-activated protein kinase in developing liver. J Biol Chem 2000; 275: 38716-38721.
5. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010; 53: 2345-2353.
6. Fausto N, Mead JE, Gruppuso PA, Braun L. TGF-beta in liver development, regeneration, and carcinogenesis. Ann N Y Acad Sci 1990; 593: 231-242.
7. Mendelson KG, Contois LR, Tevosian SG, Davis RJ, Paulson KE. Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver. Proc Natl Acad Sci U S A 1996; 93: 12908-12913.
8. Hirano F, Komura K, Fukawa E, Makino I. Tumor necrosis factor alpha (TNF-alpha)-induced RANTES chemokine expression via activation of NF-kappaB and p38 MAP kinase: roles of TNF-alpha in alcoholic liver diseases. J Hepatol 2003; 38: 483-489.
9. Kumar S, Boehm J, Lee JC. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-726.
10. Serviddio G, Pereda J, Pallardo FV, Carretero J, Borras C, Cutrin J, et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. HEPATOLOGY 2004; 39: 711-720.
11. Georgiev P, Jochum W, Heinrich S, Jang JH, Nocito A, Dahm F, et al. Characterization of time-related changes after experimental bile duct ligation. Br J Surg 2008; 95: 646-656.
12. Arduini A, Serviddio G, Tormos AM, Monsalve M, Sastre J. Mitochondrial dysfunction in cholestatic liver diseases. Front Biosci (Elite Ed) 2012; 4: 2233-2252.
13. Ventura J, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, et al. p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 2007; 39: 750-758.
14. Wu R, Kausar H, Johnson P, Montoya-Durango DE, Merchant M, Rane MJ. Hsp27 regulates akt activation and polymorphonuclear leukocyte apoptosis by scaffolding MK2 to akt signal complex. J Biol Chem 2007; 282: 21598-21608.
15. Ambrosino C, Iwata T, Scafoglio C, Mallardo M, Klein R, Nebreda AR. TEF-1 and C/EBPbeta are major p38alpha MAPK-regulated transcription factors in proliferating cardiomyocytes. Biochem J 2006; 396: 163-172.
16. Cha H, Wang X, Li H, Fornace AJJr. A functional role for p38 MAPK in modulating mitotic transit in the absence of stress. J Biol Chem 2007; 282: 22984-22992.
17. Haga S, Ozaki M, Inoue H, Okamoto Y, Ogawa W, Takeda K, et al. The survival pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation. HEPATOLOGY 2009; 49: 204-214.
18. Faridi J, Fawcett J, Wang L, Roth RA. Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation. Am J Physiol Endocrinol Metab 2003; 285: E964-E972.
19. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-1128.
20. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010; 429: 403-417.
21. Bikkavilli RK, Feigin ME, Malbon CC. p38 mitogen-activated protein kinase regulates canonical wnt-beta-catenin signaling by inactivation of GSK3beta. J Cell Sci 2008; 121( Pt 21): 3598-3607.
22. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90.
23. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002; 283: G204-G211.
24. Lee J, Hong F, Kwon S, Kim SS, Kim DO, Kang HS, et al. Activation of p38 MAPK induces cell cycle arrest via inhibition of Raf/ERK pathway during muscle differentiation. Biochem Biophys Res Commun 2002; 298: 765-771.
25. Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev 2005; 19: 1175-1187.
26. Perdiguero E, Ruiz-Bonilla V, Gresh L, Hui L, Ballestar E, Sousa-Victor P, et al. Genetic analysis of p38 MAP kinases in myogenesis: Fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J 2007; 26: 1245-1256.
27. Margall-Ducos G, Celton-Morizur S, Couton D, Bregerie O, Desdouets C. Liver tetraploidization is controlled by a new process of incomplete cytokinesis. J Cell Sci 2007; 120( Pt 20): 3633-3639.
28. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007; 17: 157-162.
29. Celton-Morizur S, Merlen G, Couton D, Margall-Ducos G, Desdouets C. The insulin/Akt pathway controls a specific cell division program that leads to generation of binucleated tetraploid liver cells in rodents. J Clin Invest 2009; 119: 1880-1887.
30. Rousseau S, Dolado I, Beardmore V, Shpiro N, Marquez R, Nebreda AR, et al. CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway. Cell Signal 2006; 18: 1897-1905.
31. Paul C, Manero F, Gonin S, Kretz-Remy C, Virot S, Arrigo AP. Hsp27 as a negative regulator of cytochrome C release. Mol Cell Biol 2002; 22: 816-834.
32. Rannou Y, Salaun P, Benaud C, Khan J, Dutertre S, Giet R, et al. Mnk1 kinase activity is required for abscission. J Cell Sci 2012; 125( Pt 12): 2844-2852.
33. Tang J, Yang X, Liu X. Phosphorylation of Plk1 at Ser326 regulates its functions during mitotic progression. Oncogene 2008; 27: 6635-4665.
34. Nakajima T, Nakashima T, Okada Y, Jo M, Nishikawa T, Mitsumoto Y, et al. Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease: comparison with telomere-specific quantitative FISH and p21 immunohistochemistry. Pathol Int 2010; 60: 175-183.